CWA Asset Management Group LLC Makes New Investment in AstraZeneca PLC (NASDAQ:AZN)

CWA Asset Management Group LLC acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZNFree Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,412 shares of the company’s stock, valued at approximately $266,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Hollencrest Capital Management raised its position in shares of AstraZeneca by 38.4% during the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after purchasing an additional 192 shares during the period. Capital Performance Advisors LLP bought a new position in AstraZeneca during the 3rd quarter worth $28,000. Summit Global Investments acquired a new stake in AstraZeneca in the third quarter worth $4,199,000. Portside Wealth Group LLC lifted its stake in AstraZeneca by 37.8% in the third quarter. Portside Wealth Group LLC now owns 9,276 shares of the company’s stock valued at $723,000 after buying an additional 2,545 shares during the last quarter. Finally, Consolidated Planning Corp boosted its holdings in shares of AstraZeneca by 2,059.6% during the third quarter. Consolidated Planning Corp now owns 60,188 shares of the company’s stock valued at $4,689,000 after acquiring an additional 57,401 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen lifted their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $89.75.

View Our Latest Research Report on AstraZeneca

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $65.19 on Wednesday. The stock’s 50 day moving average price is $76.61 and its 200 day moving average price is $78.54. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The stock has a market cap of $202.13 billion, a price-to-earnings ratio of 31.30, a PEG ratio of 1.19 and a beta of 0.47. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.

AstraZeneca Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

See Also

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.